Physician profile
Amber Woods
NPI 1669181665
$381.83
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $164 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $97.40 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $46.36 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.03 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $34.19 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.21 | 2024 | Jardiance |
| Exact Sciences Corporation | $19.08 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $18.20 | 2024 | Xarelto |
| Dexcom, INC. | $17.48 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $15.96 | 2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $14.44 | 2024 | Farxiga |
| Novo Nordisk INC | $14.19 | 2025 | Ozempic |
| Mylan Specialty L.P. | $14.06 | 2024 | Yupelri |
| Dynavax Technologies Corporation | $13.86 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $13.37 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.